The Treatment of Manic Psychoses by the Administration of Lithium Salts

Schou, Mogens; Juel-Nielsen, N; Strömgren, Erik; Voldby, H

doi:10.1136/jnnp.17.4.250

Cited by 517 publications

(163 citation statements)

References 11 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…Lithium therefore has clearly the largest pool of studies. Four early studies, starting with Schou's evaluation from 1954 (Schou et al 1954), tested lithium against placebo. However, only more recent studies, starting with a threearm study comparing valproate and lithium against placebo can be considered to fulfil current methodological standards for a drug approval study.…”

Section: Lithiummentioning

confidence: 99%

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania

Grunze

Vieta

Goodwin

et al. 2009

The World Journal of Biological Psychiatry

318

247

View full text Add to dashboard Cite

These updated guidelines are based on a first edition that was published in 2003, and have been edited and updated with the available scientific evidence until end of 2008. Their purpose is to supply a systematic overview of all scientific evidence pertaining to the treatment of acute mania in adults. The data used for these guidelines have been extracted from a MEDLINE and EMBASE search, from the clinical trial database clinicaltrials.gov, from recent proceedings of key conferences, and from various national and international treatment guidelines. Their scientific rigor was categorised into six levels of evidence (AÁF). As these guidelines are intended for clinical use, the scientific evidence was finally asigned different grades of recommendation to ensure practicability.

show abstract

Section: Lithiummentioning

confidence: 99%

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania

Grunze

Vieta

Goodwin

et al. 2009

The World Journal of Biological Psychiatry

318

247

View full text Add to dashboard Cite

show abstract

“…They also reported on the relationship between plasma level and toxicity. They laid the groundwork for clinical and laboratory monitoring and, taken in conjunction with the critical placebo-controlled study of Schou et al (1954), confirming the observations of Cade, set the stage that would have allowed the safe and effective use of lithium. However, the profession turned against lithium both here and overseas.…”

mentioning

confidence: 71%

Lithium--Early Development, Toxicity, and Renal Function

Johnson

1998

Neuropsychopharmacology

View full text Add to dashboard Cite

“…Lithium represents an important therapeutic option in mood disorders, since its first clinical study by Mogens Schou in 1954 1 . After almost 70 years of medical research, lithium salts have been shown effective for the protection against mania and depression, especially in the acute and long-term management of bipolar disorder 2 , and reducing both suicide and mortality in mood disorders 3,4 .…”

Section: Introductionmentioning

confidence: 99%

Lithium safety and tolerability in mood disorders: a critical review

Aprahamian¹,

Sousa²,

Valiengo³

et al. 2014

Rev. psiquiatr. clín.

View full text Add to dashboard Cite

Background: Lithium is a first-line treatment for bipolar disorder in all phases, also indicated as add-on drug for unipolar depression and suicide prevention. This study encompasses a broad critical review on the safety and tolerability of lithium for mood disorders. Methods: A computerized search for English written human studies was made in MEDLINE, using the keywords "lithium" and "mood disorders", starting from July 1993 through July 2013 (n = 416). This initial search aimed to select clinical trials, prospective data, and controlled design studies of lithium treatment for mood disorders reporting adverse effects (n = 36). The final selection yielded 91 studies. Results: The most common general side effects in patients on lithium treatment were thirst, frequent urination, dry mouth, weight gain, fatigue and cognitive complaints. Lithium users showed a high prevalence of hypothyroidism, hyperparathyroidism, and decrease in urinary concentration ability. Reduction of glomerular filtration rate in patients using lithium was also observed, but in a lesser extent. The evidence of teratogenicity associated with lithium use is not well established. Anti-inflammatory non-steroidal drugs, thiazide diuretics, angiotensin-converting enzyme inhibitors, and alprazolam may increase serum lithium and the consequent risk for intoxication. Discussion: Short-term lithium treatment is associated with mild side effects. Medium and long-term lithium treatment, however, might have effects on target organs which may be prevented by periodical monitoring. Overall, lithium is still a safe option for the treatment of mood disorders.

show abstract

The Treatment of Manic Psychoses by the Administration of Lithium Salts

Cited by 517 publications

References 11 publications

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania

The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2009 on the Treatment of Acute Mania

Lithium--Early Development, Toxicity, and Renal Function

Lithium safety and tolerability in mood disorders: a critical review

Contact Info

Product

Resources

About